ALC Stock Recent News

Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.

While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Alcon Inc. shares ALC, +4.04% dropped more than 4% premarket on Wednesday after the eye care company on Tuesday reported third-quarter revenues below analysts' expectations.

Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.

Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.

Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.

Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.

Here is how Alcon (ALC) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Alcon (ALC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.